Semaglutide in obesity-related heart failure with preserved ejection fraction Page 1
Semaglutide in obesity-related heart failure with preserved ejection fraction Semaglutide versus …

Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …

Introduction: Obesity-related heart failure in patients is often associated with high symptom
burden. However, no treatments have been proven to specifically target obesity-related …

Background More women than men have heart failure with preserved ejection fraction
(HFpEF). Objectives The purpose of this study was to assess baseline characteristics and …

Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Background Semaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, has
shown promise in weight management and cardiovascular outcomes in other populations …

Abstract Background and Aims In the STEP-HFpEF trial program, treatment with semaglutide
resulted in multiple beneficial effects in patients with obesity-related heart failure with …

Background Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse
cardiovascular events (MACE) in people with overweight or obesity, but the effects of this …

Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent condition,
particularly among the aging population in the United States, and is associated with …

• The Semaglutide Treatment Effect in People with obesity and heart failure with preserved
ejection fraction (STEP-HFpEF) is a companysponsored, double-blind, placebo-controlled …